MTVA
HEALTHCAREMetaVia Inc
Live · NASDAQ · May 8, Close
What's Moving MTVA Today?
No stock-specific AI insight has been generated for MTVA yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$1.40
Fundamentals
Trading
MTVA News
20 articles- MetaVia Doses the First Patient in Higher-Dose Phase 1 Study of DA-1726, Its GLP-1 and Glucagon Dual Agonist for the Treatment of ObesityYahoo Finance·Apr 10, 2026
- MTVA: Phase 1 Part 3 16-Week Titration Study of DA-1726 to Initiate in April 2026…Yahoo Finance·Mar 31, 2026
- MetaVia Reports Year End 2025 Financial Results and Provides Corporate UpdateYahoo Finance·Mar 26, 2026
- OTC Markets Hosts Virtual Investor Presentation with H.H. Kim, CEO and President of MetaVia, and David Bautz, PhD, Senior Analyst at Zacks SCRYahoo Finance·Mar 19, 2026
- MetaVia Advances GLP-1-Based Obesity Program with IRB Approval for Higher-Dose Phase 1 Studies of DA-1726, a GLP-1 and Glucagon Dual Agonist Demonstrating Best-in-Class Potential for Weight Loss and Glucose ControlYahoo Finance·Mar 18, 2026
- Life Sciences Virtual Investor Forum Presentations Now Available for Online ViewingYahoo Finance·Mar 13, 2026
- MetaVia Expands Global Patent Protection for Vanoglipel, Supporting Metabolic and Liver Disease Therapy Through 2035Yahoo Finance·Mar 12, 2026
- Life Sciences Virtual Investor Forum Agenda Announced for March 11th & 12thYahoo Finance·Mar 10, 2026
- MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Life Sciences Virtual Investor ForumYahoo Finance·Mar 4, 2026
- Presenting on Emerging Growth Conference 90 Day 1 on February 25; Register to live streamYahoo Finance·Feb 24, 2026
- MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Emerging Growth ConferenceYahoo Finance·Feb 17, 2026
- MetaVia Builds Comprehensive Global Patent Protection for DA-1726, Securing Exclusive Rights to Novel Obesity and Metabolic Therapy Through 2041Yahoo Finance·Feb 13, 2026
- MetaVia Announces Positive AI-Modeling Results from its Ongoing Syntekabio Collaboration, Confirming Key Therapeutic Targets for VanoglipelYahoo Finance·Feb 4, 2026
- MTVA: Positive Results for 48 mg Cohort in Phase 1b Trial of DA-1726…Yahoo Finance·Jan 21, 2026
- MetaVia Announces the Closing of $9.3 Million Underwritten Public Offering, Including Full Exercise of Allotment OptionYahoo Finance·Jan 16, 2026
- MetaVia Announces the Pricing of $8.1 Million Underwritten Public OfferingYahoo Finance·Jan 15, 2026
- MetaVia Reports Positive Statistically Significant Results from Its Phase 1b Clinical Trial of DA-1726 In Metabolic Disease - Demonstrating Strong Glycemic Response, Significant Direct Hepatic Effects, Robust Weight Loss and Favorable Safety ProfileYahoo Finance·Jan 5, 2026
- MetaVia to Participate in and Sponsor the 10th Annual MASH-TAG 2026 ConferenceYahoo Finance·Dec 29, 2025
- MetaVia Regains Compliance with Nasdaq Minimum Bid Price RequirementYahoo Finance·Dec 22, 2025
- MTVA: New Data for Vanoglipel (DA-1241) Presented at AASLD…Yahoo Finance·Dec 11, 2025
All 20 articles loaded
Price Data
52-Week Range
$1.40
Fundamentals
Trading
About MetaVia Inc
MetaVia Inc. is a forward-thinking technology company specializing in advanced digital solutions that drive connectivity and productivity across multiple sectors. Utilizing state-of-the-art artificial intelligence and cloud computing, MetaVia provides scalable platforms that cater to the unique requirements of its varied clientele. The company's dedication to sustainability and social responsibility not only meets evolving market expectations but also positions it for significant growth. With a strategic focus on adaptability and collaboration, MetaVia is well-positioned to capitalize on opportunities in the fast-evolving technology landscape, aiming to deliver substantial value to shareholders.